A retrospective, observational, real-world study of Dolutegravir 50 mg + Rilpivirine 25 mg in HIV infected patients who have failed prior regimen
Latest Information Update: 30 Dec 2016
At a glance
- Drugs Dolutegravir (Primary) ; Rilpivirine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 30 Dec 2016 New trial record